Dey launches new COPD drug
NAPA, Calif. Dey, a subsidiary of Mylan has launched a new drug for the treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease.
The Perforomist Inhalation Solution will be used with a nebulizer that converts the powder into a mist that patients inhale through a mouthpiece or facemask. The medication is prescribed to be taken twice daily, once in the morning and again in the evening.
“Since patients have difficulty adhering to complicated medication regimens, it’s very helpful that Perforomist Inhalation Solution offers a twice-daily nebulized version of formoterol. I consider nebulization to be an especially effective way to deliver medication into the lungs, and this new product should provide a valuable treatment for COPD patients,” said to Donald Tashkin, professor of medicine at the David Geffen School of Medicine of UCLA.
COPD is the fourth leading cause of death in America, killing about 120,000 people each year.